

REMARKS

Claims 1-42 are pending. Claim 37 has been withdrawn. Support for the amendments to the claims may be found in the original claims, Tables 62 and 70. For ease of viewing, claim 33 has been amended; it should be noted that some modifications were deleted and then re-added. Amendment to and cancellation of the claims does not affect inventorship.

Restriction Requirement

The Examiner requires Applicants to elect one of the following groups of inventions:

- I. Claims 1-36, drawn to a variant protein comprising an Fc region and a pharmaceutical composition comprising at least one amino acid modification in the Fc region, classified in class 530, subclass 395 and class 435, subclass 810.
- II. Claim 37, drawn to a method of treating a mammal by administering a variant, classified in class 424, subclass 133.1.

Applicants elect **Group I, claims 1-36**, drawn to a variant protein comprising an Fc region and a pharmaceutical composition comprising at least one amino acid modification in the Fc region, without traverse.

Species Election

The Examiner further requires a species election as follows:

- (1). a **specific** isotype from which the variant is derived;
- (2). a **specific** set of positions as recited in claim 2;
- (3). a **specific** substitution as recited in claim 33;
- (4). which, if any of the **functional limitations** recited, e.g., in claims 3-17, are encompassed by the elected antibody species; and
- (5). a **specific** glycoform (e.g. engineered) as recited in claim 18.

Applicants elect the following species:

- (1). IgG1
- (2). 332
- (3). 332E
- (4). Claims 3-7, 9 and 13.
- (5). Non-engineered glycoforms

Claims 1-7, 9, 13, 17-36, 38 and 39 read on the elected species. However, it should be noted that this recitation is based on the elected species, position 332, as a single substitution; when modifications at

position 332 is utilized in addition to other positions, the FcyR binding affinity profiles may change, potentially affecting claims 8, 10-12, and 14-16.

Although the Applicants do not believe any additional fees are required, the Commissioner is authorized to charge any additional fees, including extension fees or other relief, which may be required, or credit any overpayment to Deposit Account No. 50-2319 (Our Order A71386-8/RMS/TAW).

The Examiner is invited to contact the undersigned at (415) 781-1989 if any issues may be resolved in that manner.

Dated: December 13, 2005

Customer No.: 32940
Dorsey & Whitney LLP
Suite 1000
555 California Street
San Francisco, California 94104-1513
Telephone: (415) 781-1989
Fax No. (415) 398-3249

Respectfully submitted,

DORSEY & WHITNEY, LLP

By: _____



Timothy A. Worrall, Reg. No. 54,552
for Robin M. Silva, Reg. No. 38,304

Filed under 37 C.F.R. §1.34

4847-9297-6128\112/8/2005 4:03 PM